详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Soo, R.[1] * ; Mok, T. S. K.[2] ; Shi, Y-K.[3,4] ; Zhang, L.[5] ; Lu, S.[6] ; Yang, J. C-H.[7] ; Nakagawa, K.[8] ; Yamamoto, N.[9] ; Nokihara, H.[10] ; Sugawara, S.[11] ; Nishio, M.[12] ; Takahashi, T.[13] ; Goto, K.[14] ; Chang, J.[15] ; Maemondo, M.[16] ; Ichinose, Y.[17] ; Cheng, Y.[18] ; Lim, W.[19] ; Morita, S.[20] ; Tamura, T.[21] ;

机构： [1]Natl Univ Singapore Hosp, Haematol Oncol, Singapore, Singapore; [2]Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [3]Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticanc Mol Targeted, Natl Canc Ctr, Med Oncol,Canc Hosp, Beijing, Peoples R China; [4]Peking Union Med Coll, Beijing, Peoples R China; [5]Sun Yat Sen Univ, Ctr Canc, Med Oncol, Guangzhou, Guangdong, Peoples R China; [6]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China; [7]Natl Taiwan Univ Hosp, Oncol, Taipei, Taiwan; [8]Kindai Univ, Sch Med, Med Oncol, Osaka, Japan; [9]Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan; [10]Natl Canc Ctr, Thorac Oncol, Tokyo, Japan; [11]Sendai Kousei Hosp, Pulm Med, Sendai, Miyagi, Japan; [12]Canc Inst Hosp JFCR, Thorac Med Oncol, Tokyo, Japan; [13]Shizuoka Canc Ctr, Thorac Oncol, Shizuoka, Japan; [14]Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan; [15]Fudan Univ, Shanghai Canc Ctr, Med Oncol, Shanghai, Peoples R China; [16]Miyagi Canc Ctr, Thorac Oncol, Natori, Miyagi, Japan; [17]Kyushu Natl Canc Ctr, Canc Infomat Res, Fukuoka, Japan; [18]Jilin Prov Canc Hosp, Thorac Oncol, Changchun, Jilin, Peoples R China; [19]Natl Canc Ctr Singapore, Med Oncol, Singapore, Singapore; [20]Kyoto Univ, Grad Sch Med, Biomed Stat & Bioinformat, Kyoto, Japan; [21]St Lukes Int Hosp, Thorac Ctr, Tokyo, Japan

出处：

DOI：

ISSN：

基金：

语种：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

第一作者：

第一作者机构： [1]Natl Univ Singapore Hosp, Haematol Oncol, Singapore, Singapore;

推荐引用方式(GB/T 7714)：

APA：

MLA：

EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs)

文献详情